195 related articles for article (PubMed ID: 18049892)
1. Commentary to "Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease".
Mandal PK; Pettegrew JW
Neurochem Res; 2008 Jun; 33(6):1168. PubMed ID: 18049892
[No Abstract] [Full Text] [Related]
2. Interaction between Abeta peptide and alpha synuclein: molecular mechanisms in overlapping pathology of Alzheimer's and Parkinson's in dementia with Lewy body disease.
Mandal PK; Pettegrew JW; Masliah E; Hamilton RL; Mandal R
Neurochem Res; 2006 Sep; 31(9):1153-62. PubMed ID: 16947080
[TBL] [Abstract][Full Text] [Related]
3. Collusion of α-Synuclein and Aβ aggravating co-morbidities in a novel prion-type mouse model.
Lloyd GM; Dhillon JS; Gorion KM; Riffe C; Fromholt SE; Xia Y; Giasson BI; Borchelt DR
Mol Neurodegener; 2021 Sep; 16(1):63. PubMed ID: 34503546
[TBL] [Abstract][Full Text] [Related]
4. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum.
Sierra M; Gelpi E; Martí MJ; Compta Y
Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462
[TBL] [Abstract][Full Text] [Related]
5. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia.
Fujishiro H; Iseki E; Higashi S; Kasanuki K; Murayama N; Togo T; Katsuse O; Uchikado H; Aoki N; Kosaka K; Arai H; Sato K
Neurosci Lett; 2010 Dec; 486(1):19-23. PubMed ID: 20851165
[TBL] [Abstract][Full Text] [Related]
6. Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
Pletnikova O; West N; Lee MK; Rudow GL; Skolasky RL; Dawson TM; Marsh L; Troncoso JC
Neurobiol Aging; 2005; 26(8):1183-92. PubMed ID: 15917102
[TBL] [Abstract][Full Text] [Related]
7. Non-Amyloid-β Component of Human α-Synuclein Oligomers Induces Formation of New Aβ Oligomers: Insight into the Mechanisms That Link Parkinson's and Alzheimer's Diseases.
Atsmon-Raz Y; Miller Y
ACS Chem Neurosci; 2016 Jan; 7(1):46-55. PubMed ID: 26479553
[TBL] [Abstract][Full Text] [Related]
8. Broad neutralization of calcium-permeable amyloid pore channels with a chimeric Alzheimer/Parkinson peptide targeting brain gangliosides.
Di Scala C; Yahi N; Flores A; Boutemeur S; Kourdougli N; Chahinian H; Fantini J
Biochim Biophys Acta; 2016 Feb; 1862(2):213-22. PubMed ID: 26655601
[TBL] [Abstract][Full Text] [Related]
9. Faster disease progression in Parkinson's disease with type 2 diabetes is not associated with increased α-synuclein, tau, amyloid-β or vascular pathology.
de Pablo-Fernández E; Courtney R; Rockliffe A; Gentleman S; Holton JL; Warner TT
Neuropathol Appl Neurobiol; 2021 Dec; 47(7):1080-1091. PubMed ID: 33969516
[TBL] [Abstract][Full Text] [Related]
10. Novel Benzothiazole Derivatives as Fluorescent Probes for Detection of β-Amyloid and α-Synuclein Aggregates.
Watanabe H; Ono M; Ariyoshi T; Katayanagi R; Saji H
ACS Chem Neurosci; 2017 Aug; 8(8):1656-1662. PubMed ID: 28467708
[TBL] [Abstract][Full Text] [Related]
11. beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
Masliah E; Rockenstein E; Veinbergs I; Sagara Y; Mallory M; Hashimoto M; Mucke L
Proc Natl Acad Sci U S A; 2001 Oct; 98(21):12245-50. PubMed ID: 11572944
[TBL] [Abstract][Full Text] [Related]
12. A critical evaluation of current staging of alpha-synuclein pathology in Lewy body disorders.
Jellinger KA
Biochim Biophys Acta; 2009 Jul; 1792(7):730-40. PubMed ID: 18718530
[TBL] [Abstract][Full Text] [Related]
13. Convergence of pathology in dementia with Lewy bodies and Alzheimer's disease: a role for the novel interaction of alpha-synuclein and presenilin 1 in disease.
Winslow AR; Moussaud S; Zhu L; Post KL; Dickson DW; Berezovska O; McLean PJ
Brain; 2014 Jul; 137(Pt 7):1958-70. PubMed ID: 24860142
[TBL] [Abstract][Full Text] [Related]
14. Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity.
Aarsland D; Londos E; Ballard C
Int Psychogeriatr; 2009 Apr; 21(2):216-9. PubMed ID: 19173762
[No Abstract] [Full Text] [Related]
15. α-Synuclein mRNA and soluble α-synuclein protein levels in post-mortem brain from patients with Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease.
Quinn JG; Coulson DT; Brockbank S; Beyer N; Ravid R; Hellemans J; Irvine GB; Johnston JA
Brain Res; 2012 Jun; 1459():71-80. PubMed ID: 22560502
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterisation of BF227 binding to alpha-synuclein/Lewy bodies.
Fodero-Tavoletti MT; Mulligan RS; Okamura N; Furumoto S; Rowe CC; Kudo Y; Masters CL; Cappai R; Yanai K; Villemagne VL
Eur J Pharmacol; 2009 Sep; 617(1-3):54-8. PubMed ID: 19576880
[TBL] [Abstract][Full Text] [Related]
17. Molecular imaging of dementia.
Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
[TBL] [Abstract][Full Text] [Related]
18. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
Schell H; Hasegawa T; Neumann M; Kahle PJ
Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
[TBL] [Abstract][Full Text] [Related]
19. Striatal β-amyloid in dementia with Lewy bodies but not Parkinson's disease.
Halliday GM; Song YJ; Harding AJ
J Neural Transm (Vienna); 2011 May; 118(5):713-9. PubMed ID: 21479514
[TBL] [Abstract][Full Text] [Related]
20. Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases.
Williams SM; Schulz P; Sierks MR
Eur J Neurosci; 2016 Jan; 43(1):3-16. PubMed ID: 26332448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
